Why Fatal 'Flesh-Eating' Bacteria Infections Are On The Rise
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Fatal infections from "flesh-eating" bacteria Vibrio vulnificus are on the rise, with eight deaths and dozens more cases already this year, and experts warn that climate change is in part to blame.
"Available data indicates that infections are indeed on the rise, particularly in the Gulf Coast and surrounding regions," Antarpreet Jutla, a professor and director of the USGS FL Water Resources Research Center, and director of the GeoHealth and Hydrology Laboratory at the University of Florida, told Newsweek.
"Climate change is likely a major reason," R. Sean Norman, a professor and director of the Molecular Microbial Ecology Laboratory in the Department of Environmental Health Sciences at the University of South Carolina, told Newsweek.
Why This Matters
The deadly bacteria thrives in coastal regions where millions of Americans head for holidays, and with sea temperatures rising, an increase in severe storms, and other environmental changes linked to climate change, experts fear that the number of Vibrio vulnificus infections each year will only continue to rise.
What Is Vibrio Vulnificus?
Vibrio vulnificus is a bacterium the Vibrio family, that is often labeled "flesh-eating" for its ability to cause severe and sometimes fatal tissue damage.
Around 150 to 200 Vibrio vulnificus infections are reported to the CDC a year, with about one in five cases being fatal.
Vibrio bacteria live in coastal waters, including salt water and brackish water, a mixture of salt water and fresh water. While most people get infected with Vibrio by eating raw or undercooked shellfish, particularly oysters, some may get infected when an open wound is exposed to salt water or brackish water containing Vibrio, which is how people can become infected with Vibrio vulnificus.
Symptoms of Vibrio vulnificus wound infections include redness, swelling, fever and others, while bloodstream infections can result in fever, dangerously low blood pressure and blistering.
Vibrio vulnificus infections can lead to serious and life threatening complications, such as if flesh around an infected wound dies.
While anyone can get infected, those with weakened immune systems, chronic liver, kidney, or heart disease, cancer, or diabetes, or individuals with fresh wounds are most at risk.
Newsweek Illustration/Getty
The Impact Of Climate Change
Rita Colwell, a microbiologist and marine scientist at the University of Maryland College Park and former director of the National Science Foundation, agreed the incidence of Vibrio vulnificus infections is "definitely on the rise," and is well documented along the Gulf Coast and the Southeastern coastal regions of the Eastern United States.
Jutla said that several factors are contributing to this increase, such as increasing sea surface temperatures. "Warmer waters create more favorable conditions for Vibrio proliferation," he said.
Colwell also said that the "warming of the oceans related to climate change is playing a direct role in this public health threat as warmer temperatures are selective for growth of Vibrios, bacteria that are a natural component of the microbial communities in aquatic ecosystems."
She added that her research team has "clearly shown an increase in reported Vibrio vulnificus infections moving northward, as the coastal water temperatures have been gradually rising along the East Coast as far as Connecticut and Rhode Island, where cases and deaths were reported very recently."
The warming sea temperatures have an enhancing effect on the prevalence of Vibrio bacteria because "this bacteria thrives in warm, salty, or brackish water, and as ocean temperatures increase, it can survive for more of the year and spread to new areas," Norman said.
Alongside increasing sea temperatures, "more frequent and intense storms can also wash extra nutrients into the water, creating ideal conditions for Vibrio to grow," he said.
"In short, warmer waters and more nutrients mean more Vibrio, and a higher risk for people swimming or coming into contact with coastal waters," he added.
Other factors impacting the prevalence of the bacteria include enhanced planktonic activity, Jutla said, as Vibrio "often associates with plankton, and increased plankton blooms may support larger bacterial populations."
Nutrient runoff from land could be another piece of the puzzle, Jutla said, as "agricultural and urban runoff may enrich coastal waters, further promoting microbial growth."
"Given these trends, it's reasonable to expect that the risk of encountering Vibrio vulnificus in certain coastal waters—especially during warmer months—will continue to grow," he said. "This underscores the importance of public awareness and preventive measures."
Cases Of Vibrio Vulnificus Infections This Year
The eight deaths happened across Florida and Louisiana, with four in each state. Nine other states have also had cases of Vibrio vulnificus infections, according to the news outlet today.com, citing state sources and the Centers for Disease Control and Prevention (CDC)'s BEAM (Bacteria, Enterics, Ameba, and Mycotics) Dashboard.
Per the outlet, in total, there have been 57 confirmed cases of the infection caused by the bacteria in the U.S. this year.
The 57 cases of confirmed Vibrio vulnificus infections this year spread across the 11 following states:
Alabama (three cases)
Arizona (one case)
Florida (13 cases, four deaths)
Georgia (two cases)
Louisiana (17 cases, four deaths)
Massachusetts (one case)
Mississippi (one case)
North Carolina (seven cases)
South Carolina (one case)
Texas (five cases)
Virginia (six cases)
Recent years have seen infections and deaths rise following extreme storms and during periods of elevated water temperatures.
In 2024, Florida had a record 82 cases and 19 deaths, a surge health officials linked to hurricane-induced flooding and warm coastal waters.
In order to protect yourself from infection with the bacteria, there are a number of things you can do.
These measures include avoiding contact with salt or brackish water if you have open wounds, thoroughly cooking all shellfish and using waterproof bandages on wounds if exposure is likely.
Showering and washing with soap after swimming, and promptly washing wounds exposed to coastal water is also important, as is washing hands and surfaces after handling raw seafood.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 hours ago
- Newsweek
New Species of Reptile Named After Discovery of 'Extremely Rare' Fossil
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Paleontologists from Petrified Forest National Park and the Smithsonian National Museum of Natural History named and described a new species of "unusual, long-necked reptile" after microfossils of the animal were recovered at a site called Thunderstorm Ridge in northern Arizona. Newsweek has reached out to the Petrified Forest National Park by email for comment. Why It Matters Thousands of new species are discovered each year, and many of these are classified as endangered or already extinct. For example, the new reptile found in the Petrified Forest National Park in Arizona lived more than 200 million years ago. The species' description, based on tiny screen‑washed fossils and published in the peer‑reviewed journal Palaeodiversity, documented anatomy consistent with tanystropheid reptiles—a group known for extreme neck elongation in some species—and indicated that the Triassic landscape of northern Arizona was warm and wet about 220 million years ago, supporting swampy ponds and small rivers where these animals may have lived. What To Know Scientists named the new species Akidostropheus oligos, which translates to "tiny, spiked back bone." The reptile is so named because its neck bones are smaller than the average pinky fingernail and have a unique spike on the top. Akidostropheus oligos is known as a tanystropheid reptile, a type of animal that can have a neck that is "twice as long as the body and tail combined," the press release said. The fossils were discovered at the Thunderstorm Ridge site, within the Petrified Forest. The discovery was made after assessing microfossils, which were found by "collecting large amounts of rock from the site, rinsing that rock with water through fine metal screens to break it down, and then looking at the remaining sediment under a microscope to find the tiny fossils." "The study, led by seasonal paleontologist Alaska Schubert, describes the anatomy of Akidostropheus oligos and compares it to other related Triassic animals from fossils that are relatively common from Europe and China but are extremely rare in North America," Petrified Forest National Park posted on Facebook earlier this month. "This study shows that 220 million years ago in the Triassic Period, northern Arizona was a warm, wet place. The tanystropheids that inhabited the area might have lived in swampy ponds or small rivers." The genus Tanystropheus was also discovered at the site, the study said. Prior to the study, there has been only one confirmed occurrence of the genus Tanystropheus in North America. An artistic rendering of a long-necked tanystrophied reptile, the group of animals to which the new discovery belongs. An artistic rendering of a long-necked tanystrophied reptile, the group of animals to which the new discovery belongs. Petrified Forest National Park What People Are Saying Paleontologist Alaska Schubert told Newsweek: "To me, the coolest thing about Akidostropheus oligos is the spike on the vertebrae: there are very few animals that have spiked bone projections; most animals (living and extinct) who exhibit spikes do so via specialized scales, skin, or hair, so it's a very unique exhibit of a defensive structure. It is also special because the clade that it belongs to, Tanystropheidae, are very rarely found in North America, so not only is this a new species, but it is a unique find on a larger ecological level that shows that the group was wider spread than previously thought." The study in Palaeodiversity said: "The new genus and species described here, Akidostropheus oligos, is a small, non-marine tanystropheid. Due to the disarticulated nature of the microfossils from PFV 456, the taxon is at this time only known from vertebrae, which precludes an investigation into many other aspects of these interesting animals, such as locomotion, diet, or braincase reconstruction for sensory analysis." What Happens Next? In its conclusion, the study notes the "emerging importance of studying Triassic non-marine microvertebrate bonebeds to fill gaps in the spatiotemporal and anatomical record of Tanystropheidae, among other groups." Schubert told Newsweek that "it's possible there are additional new species" from the assemblages at Thunderstorm Ridge "just waiting to be discovered."
Yahoo
2 hours ago
- Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression
This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to the Designation granted in 2017 for bipolar depression alone The Designation includes an FDA determination that NRX-100 has the potential to address an unmet need, based on FDA's assessment of the data submitted Determination of "unmet need" is a requirement for a Commissioner's National Priority Voucher (CNPV) program. Suicide is a public health crisis. Approximately 13 million adults seriously consider suicide each year, according to the CDC, 3.7 million make a plan to commit suicide. An American dies from suicide every 11 minutes. Active-duty personnel, veterans, and first responders have a four-fold higher risk of suicide. WILMINGTON, Del., Aug. 11, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced US Food and Drug Administration (FDA) has granted Fast Track designation to NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. This designation for NRX-100 as a standalone drug is a 10-fold expansion of the addressable population for NRX-100, compared to the designation granted in 2017 for NRX-100 in combination with NRX-101 (DCS/lurasidone) for treatment of Suicidal Bipolar Depression. In granting the Fast Track designation, FDA made the determination that NRX-100 has the potential to address an unmet medical need, based on an assessment of the preliminary data contained in the Fast Track designation request. This determination of unmet medical need aligns with the eligibility requirements for the Commissioner's National Priority Voucher Program (CNPV)i and for the FDA's Accelerated Approval The Company has applied for a CNPV, which has the potential to substantially shorten the review cycle for NRX-100. Several well-controlled trials submitted to FDA in support of Fast Track Designation demonstrated a clinically meaningful and statistically significant reduction of suicidal ideation. In a Columbia University study licensed by NRx, suicidal patients treated with intravenous ketamine demonstrated a 55% response (i.e. 50% reduction in suicidality) compared to a 30% response to active comparator (P<.02).iii In a trial sponsored by the Government of France and licensed by NRx, 63% of patients achieved full remission from suicidal ideation in three days compared to 31% of those who received placebo (P<.001). This effect has not been proven with intranasal administration of "We thank FDA for its thoughtful review of our Fast Track designation request, and believe this regulatory determination is a significant step forward in our goal to address the national crisis of suicide among soldiers, first responders, veterans, and civilians alike." said Dr. Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals. "Large-scale government-supported trials have demonstrated a robust and statistically significant reduction in suicidal ideation and depression with administration of ketamine. This drug was also proven to be non-inferior to electroshock therapy in treating depression without the negative side effects of ECT. We look forward to working closely with the FDA in our quest to Bring Hope to Life." Under the terms of the Fast Track program, NRx will be posting an expanded access policy for NRX-100 in the next two weeks and seeking a meeting with FDA leadership to finalize the data to be submitted under the Accelerated Approval / CNPV application. In addition to the benefits above, Fast Track Designation also grants enhanced communication with the FDA, as well as potential Priority Review and Rolling Review. NRX-100 in Suicidal Ideation in Patients with Depression, Including Bipolar Depression According to the CDC, approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – is designed to help address this national crisis. NRx will be submitting patient-level data from controlled clinical trials that demonstrate ketamine to be superior to both a placebo and an active comparator, as well as either non-inferior or superior to electroshock therapy in treating various forms of depression, including patients with active suicidal ideation. Although ketamine in various forms is increasingly used to treat depression and related disorders, it is currently only approved by FDA only for use as an anesthetic and, therefore, not reimbursed by most insurance carriers for treatment of suicidality or depression. Intravenous ketamine is reimbursed by the Department of Veterans Affairs and the Department of Defense for its beneficiaries. By applying for FDA labeling for NRX-100 to treat suicidal depression, the Company hopes to make this potentially life-saving therapy available to all Americans, not just those who are able to pay out of pocket. The Company has previously filed full Chemical Manufacturing and Controls (CMC) information for NRX-100 with FDA and has reported stability and sterility data sufficient to anticipate three-year room temperature shelf life for preservative-free ketamine. Having completed this Fast Track Designation, NRx is now filing draft labeling for NRX-100 to comply with the CNPV requirement. NRX-100 is the first preservative-free presentation of ketamine to be filed with FDA. Currently available product, primarily of foreign manufacture, contains a known toxic preservative, Benzethonium Chloride (BZT) that is not Generally Recognized as Safe (GRAS) and is not allowed by FDA to be used in hand cleaners and topical antiseptics. NRx demonstrated long term stability and sterility with its patented preservative-free formulation of NRX-100. The Company has additionally filed a Citizen Petition seeking to have BZT removed from all intravenous ketamine products. The Company has instituted US-based high-volume manufacture of sterile, preservative-free ketamine. Regarding Fast Track designation, FDA's website states: A drug that receives Fast Track designation is eligible for some or all of the following: More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval. More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met. Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA. NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. References i Grunebaum, et al. Ketamine for rapid reduction of suicidal thoughts… Am J Psychiatry 2018;175: Abbar, et al. Ketamine for the acute treatment of severe suicidal ideation… BMJ 2021;167:194-203 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of France, licensed under a data sharing agreement. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Matthew Duffy Chief Business Officer, NRx Pharmaceuticals mduffy@ Brian Korb Managing Partner (917) 653-5122 View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Medical debt can still appear on credit reports, judge rules
A federal judge blocked a rule from the Biden-era Consumer Financial Protection Bureau that would have kept medical debt from appearing on credit reports. Mind Your Money host Julie Hyman reports on the latest. To watch more expert insights and analysis on the latest market action, check out more Mind Your Money. A judge has blocked a Biden era ban on medical debt in credit reports. Now, technically, the rule from the Consumer Financial Protection Bureau never took effect, but if it had, it would have stopped medical bills from appearing on credit reports and barred lenders from using that data to make lending decisions. The CFPB says removing medical bill information could have wiped $49 billion off credit reports of about 15 million Americans and increased their credit scores by an average of 20 points. But a judge ruled in favor of two trade associations that argued the CFPB overstepped its authority in issuing that rule. This comes at a precarious time in health care, with millions of Americans expected to lose health insurance by 2034 due to changes in Medicaid under President Trump's new tax bill. So how does medical debt and your credit report work without this rule? Say you get medical care. The provider will send your bill to insurance, and you're responsible for whatever your insurance does not cover. If you don't pay that balance, the provider will likely send you reminders. If you still don't pay, they may send that debt to a collection agency. Once it's with the agency, they own that debt. They'll start calling and sending you letters, and they may report it to credit bureaus. Once reported, it can appear on your credit report. Now, it may not hurt your credit score right away. Medical debt must be one year old before it shows up on your credit report. Debt under $500 is not reported. And 14 states have provisions in place to remove medical collection debt from credit reports. But still, consumers are left with the responsibility to stay on top of changes to their credit as they face mounting bills.
